Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake

Esperion Therapeutics, Inc.’s cholesterol-lowering drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) have been slow to gain market traction since winning US Food and Drug Administration approval in 2020, but the company has the opportunity to expand its presence with upcoming full results from its 14,000-patient Phase III cardiovascular outcomes trial (CVOT) in statin-intolerant patients.

Esperion announced top-line results, without full data, from the placebo-controlled CLEAR Outcomes trial on 7 December, stating that the study met its primary endpoint of demonstrating statistically significant reduction in four major adverse cardiovascular events (MACE-4) – cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or coronary revascularization – and noting that it was the first oral non-statin and first ATP citrate